European Medicines Agency approves avelumab plus axitinib for first-line treatment of advanced kidney cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines [...]
Steve Pointon launches his 40 for 40 fundraising challenge
Please get behind Steve to support him during his 40 [...]
Tivozanib in heavily pre-treated advanced kidney cancer patients
Further data from the TIVO-3 clinical trial comparing tivozanib with [...]
PD-L1 expression and clinical outcomes with targeted therapy
A recent study published in Clinical Cancer Research analysed tumour [...]
Immune checkpoint inhibitors are more effective in PD-L1 positive patients
Immune checkpoint inhibitors, such as nivolumab, ipilimumab or pembrolizumab are [...]
Active surveillance versus immediate treatment in metastatic kidney cancer
A recent study has provided evidence that a subset of [...]
Ilixadencel plus sunitinib combination for metastatic kidney cancer
A combination of ilixadencel plus sunitinib has shown a complete [...]
Positive results from the 2018 NHS Cancer Patient Experience Survey
The 2018 NHS Cancer Patient Experience Survey showed that nine [...]
Personalised immunotherapy for advanced kidney cancer
In this video interview, Dr David Braun from the Dana-Farber [...]
European Commission approves pembrolizumab plus axitinib combination for first-line treatment of advanced kidney cancer
Based on the findings from the pivotal phase 3 KEYNOTE-426 [...]
